De Felice Marco, Farina Giuliana, Bianco Rosario, Monaco Giuseppe, Iaccarino Salvatore
Hematology and Medical Oncology, AORN Sant'Anna and San Sebastiano, Caserta, ITA.
Clinical Oncology, Università degli Studi della Campania "Luigi Vanvitelli", Naples, ITA.
Cureus. 2022 Jul 6;14(7):e26602. doi: 10.7759/cureus.26602. eCollection 2022 Jul.
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has drastically affected our daily lives, causing millions of deaths worldwide. The early and late complications of this infection are being increasingly revealed on a regular basis; however, an important brake on the spread and especially the lethality of the disease has been guaranteed by the introduction of mRNA-based and viral vector-based COVID-19 Vaccines. Also, an increasing number of adverse effects of the vaccination have been reported to specific pharmacovigilance boards, most of them totally non-serious events that are resolved within one to three days after the administration of the vaccine. In this report, we present a case of Evans syndrome (ES) secondary to SARS-CoV-2 vaccination in an 85-year-old male patient. To the best of our knowledge, this is the first case of ES caused by the COVID-19 vaccination to be reported in the literature.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）大流行，极大地影响了我们的日常生活，在全球范围内造成了数百万人死亡。这种感染的早期和晚期并发症正越来越频繁地被揭示出来；然而，基于信使核糖核酸（mRNA）和基于病毒载体的COVID-19疫苗的推出，为阻止该疾病的传播，尤其是其致死性起到了重要作用。此外，越来越多的疫苗接种不良反应已报告给特定的药物警戒委员会，其中大多数是完全不严重的事件，在接种疫苗后一至三天内即可解决。在本报告中，我们介绍了一名85岁男性患者接种SARS-CoV-2疫苗后继发埃文斯综合征（ES）的病例。据我们所知，这是文献中报道的首例由COVID-19疫苗引起的ES病例。
